Home > Pressrelease > Drug-Eluting Balloon Catheters Market size to exceed $916mn by 2028

Drug-Eluting Balloon Catheters Market size to exceed $916mn by 2028

  • Published Date: April 8, 2022

Drug-eluting Balloon Catheters Market size is set to surpass USD 916 million by 2028, according to a new research report by Global Market Insights Inc.

There are several factors that drives the market demand and are instrumental in the advancement of industry such as, growing prevalence of peripheral and cardiovascular diseases, technological advancements in drug coated balloon catheters, increasing preference for minimally invasive procedures and rising geriatric population globally.

Drug-eluting balloon catheters offer controlled drug delivery in order to treat cardiovascular diseases. The growing burden of the chronic diseases boost the requirement for therapeutic surgical interventions that incorporate catheters among other devices. Thus, the above-mentioned factors are anticipated to boost the drug-eluting balloon catheters market growth.

Increasing popularization for minimally invasive surgeries are expected to stimulate the market expansion

Minimally invasive procedures are popularized as they do not require longer stay at hospitals and are cost-effective. These procedures have increased life expectancy of patients and are associated with lesser pain and fewer complications which has had a favorable impact on the market value. The patient’s reliance on the minimally invasive procedures for catheter placement operations has grown as a result of low-cost technologies and cost-effective treatment.

Additionally, the rising prevalence of chronic diseases such as cardiovascular problems among adults and elderly patients is one of the major reasons foster the market revenue. Procedures to treat disorders such as atherosclerosis, incorporating drug-eluting balloon catheters aide in providing therapeutic interventions. Moreover, the patients receiving adequate care are observed to have lower risks and fewer co-morbid conditions. Thus, the rise in demand for minimally invasive procedures has notably boosted the industry landscape.

Browse key industry insights spread across 165 pages with 221 market data tables & 14 figures & charts from the report, Drug-Eluting Balloon Catheters Market Analysis By Product (Coronary Artery Disease Drug Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By End-use (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories), Industry Analysis Report, Regional Outlook , Growth Potential, Competitive Market Share & Forecast, 2022– 2028 in detail along with the table of contents:

Rising number of coronary arterial diseases is anticipated to accelerate the market progression

Drug-eluting balloon catheters market from coronary artery disease drug-eluting balloon catheters segment is projected to cross USD 413 million by 2028. Technological advancements in drug-eluting balloon catheters will boost the market forecasts. Among the primary drug identified for the drug eluting balloon catheters is paclitaxel as it provides prolonged retention and rapid uptake. The drug-eluting balloon catheters technology is demonstrated as safe and efficient in randomized clinical trials, as mentioned in one of the articles in AHA journals.

The cardiovascular disease is one of the leading causes of mortality, especially due to heart failure and ischemic heart disease, more than 1 million cardiac catheterization procedures are performed every year in the U.S. Various key industry players are coming up with strategies and developments in the catheters domain, which is predicted to propel overall market statistics.

Better patient outcomes and reduced costs in an ambulatory surgery center will enhance the overall industry outlook

Drug-eluting balloon catheters market from ambulatory surgical centers segment is likely to surpass USD 325 million by 2028. Ambulatory surgical centers (ASCs), features several modern conveniences, such as a fully capable and well-equipped operating room staffed by experienced healthcare professionals that may give same-day care. Majority of the procedures performed in an ambulatory surgical center do not require an overnight stay due to which ASCs are also known as outpatient surgery centers. ASCs have a greater autonomy; hence, it is less expensive than hospitals.

The ASCs put a strong emphasis on patient care by aiming to improve processes, care quality, and technology, resulting into higher success rate for patients. There is also a lower chance of infection because the patient is not exposed to viruses commonly in a hospital setting. Furthermore, the increased frequency of cardiovascular and peripheral diseases, and the simplicity of accessing therapy, thereby augmenting the segment value.

Growing adoption of drug eluting catheters in Germany is estimated to fuel the regional business landscape

Germany drug-eluting balloon catheters market is expected to reach USD 75 million by 2028. This is owing to the presence of large number of key market players in the region. The geriatric persons possess higher susceptibility to health issues such as cognitive disfunctions, metabolic diseases, cardiovascular diseases, etc. These health concerns are common but not universal in the aging population. Moreover, the increasing number of cardiac procedures conducted in Germany will positively influence the regional industry statistics.

Players are implementing strategic initiatives such as product launches and business expansion

Some of the major players operating in the drug-eluting balloon catheters industry are Aachen Resonance GmbH, B. Braun Melsungen AG, BD Interventional, Biosensors International, Biotronik AG, Boston Scientific Corporation, Eurocor GmbH, iVascular S.L.U., Zhejiang Barty Medical Technology Co., Ltd, Lepu Medical Technology (Beijing) Co., Ltd., MedAlliance, and Medtronic among others. These players are engaged in strategic collaborations, partnerships, and agreements to gain a competitive advantage over their competitors in the market.

For instance, in July 2021, Medtronic Plc announce the launch of Medtronic Prevail DCB in Europe. During percutaneous coronary intervention (PCI) operations, the drug coated balloon (DCB) catheter is used to treat restricted coronary arteries in patients with coronary artery disease (CAD). The Prevail DCB incorporates a quick absorption medication called paclitaxel to enable treatment. New product launches such as these have helped the company improve its product line and increase its drug-eluting balloon catheters portfolio in the European market.

Authors: Sumant Ugalmugle, Rupali Swain